Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Genitourinary 1Endocrine 1

Conditions

Thyroid Cancer, Papillary 1Somatostatinoma 1Sarcoma, Endometrial Stromal 1Pheochromocytoma 1Melanoma 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Adrenocortical Adenoma 1Adenocarcinoma, Follicular 1

Interventions

Nivolumab 2Bortezomib 2vatalanib 1tovorafenib 1tipifarnib 1spartalizumab 1sargramostim 1romidepsin 1pentetreotide 1pasireotide 1milademetan 1fludarabine phosphate 1entrectinib 1entinostat 1dabrafenib 1cobimetinib 1avelumab 1alectinib 1aldesleukin 1Vemurafenib 1Taxes 1Specimen Handling 1Rose Bengal 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1PLX8394 1Molecular Diagnostic Techniques 1Microscopy, Electron 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × High-Energy Shock Waves × Endocrine × Clear all
NCT00655655 2024-08-21

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Mayo Clinic

Phase 1 Completed
96 enrolled
DermatologicEndocrineGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Melanoma, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡